Zanubrutinib in Patients With IgG4-Related Disease

NCT04602598 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

IgG4 Related Disease

Interventions

DRUG: Zanubrutinib 80 MG

Sponsor

Matthew C. Baker

Collaborators

[object Object]